Latest News and Press Releases

Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...

Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global Protein Expression Market Report by Product, Application, End User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's...

ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...

Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.

Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.

Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Cancer Cachexia - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Cancer Cachexia Market to Reach...

Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Global Cytokine Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's...

Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...

Wilmington, Delaware, United States, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global adjuvants market is estimated to flourish at a CAGR of 6.7% from 2022 to 2031....